Intravenous plus intraventricular tigecycline-amikacin therapy for the treatment of carbapenem-resistant *Klebsiella pneumoniae* ventriculitis

A case report

Jiyao Li, MMed*, Yiguo Liu, BPharm, Guangtao Wu, BPharm, Hongyan Wang, BPharm, Xiaoyan Xu, BPharm

Abstract

Rationale: Central nervous system infections (CNSIs) are one of the most serious complications after neurosurgery, especially carbapenem-resistant bacterial meningitis. Owing to the poor blood-brain barrier permeability of most antibiotics, the treatment of CNSIs by intraventricular (IVT) administration is becoming a hot topic in clinical research. Currently, the treatment of CNSIs caused by carbapenem-resistant *Klebsiella pneumoniae* is mainly based on intraventricular injection of an antibiotic combined with one or more other systemic intravenous (IV) antibiotics, whereas there are few case reports of intraventricular injection of 2 antibiotics.

Patient concerns: A 57-year-old man with an open craniocerebral injury presented with dyspnea, high fever, and seizures associated with surgery.

Diagnosis: Intracranial infection caused by carbapenem-resistant *K. pneumoniae* was diagnosed.

Interventions: On the advice of a clinical pharmacist, the patient was given tigecycline (100 mg IV + 3 mg IVT q12h) combined with amikacin (0.8 g IV + 30 mg IVT qd) antifibative therapy. Ultimately, the pathogens in the cerebrospinal fluid were eradicated after 7 days, and the CNSIs were completely cured after 14 days.

Outcomes: The patient recovered and was discharged from the hospital without adverse reactions.

Lessons: A series of in vitro and in vivo synergy tests of carbapenem-resistant *K. pneumoniae* showed that tigecycline combined with aminoglycosides had good synergistic effects and effectively suppressed bacterial resistance selection. Intravenous plus intraventricular tigecycline-amikacin seems to be a safe and effective treatment option for carbapenem-resistant *K. pneumoniae* CNSIs.

Abbreviations: CNSIs = Central nervous system infections, CRKP = Carbapenem-resistant *K. pneumoniae*, IVT = intraventricular, CSF = cerebrospinal fluid, IV = intravenous, LMR = leukocyte multinucleate ratio, MIC = minimal inhibitory concentration, PCT = procalcitonin, WBC = white blood cell.

Keywords: Carbapenem-resistant Klebsiella pneumoniae, tigecycline, amikacin, intraventricular, central nervous system infections.

1. Introduction

Central nervous system infections (CNSIs) caused by gram-negative bacteria are one of the most serious complications of craniocerebral surgery and significantly affect the prognosis. In recent years, multidrug-resistant Enterobacteriaceae, especially *K. pneumoniae*, have emerged with the increasing use of broad-spectrum antibacterial agents. To make matters worse, the carbapenem-resistant *K. pneumoniae* (CRKP) is prevalent in patients with nosocomial infections in the United States, China, Colombia, Brazil, Argentina and a few European countries. According to data from the China Antimicrobial Surveillance Network (CHINET), the resistance rates of *K. pneumoniae* to meropenem and imipenem rapidly increased from 2.9 and 3.0% in 2005 to 27.1 and 25.5% in 2021, respectively. The treatment of CNSIs caused by CRKP is a difficult problem for clinicians, for the following reasons: (1) *K. pneumoniae* carbapenemase can effectively hydrolyze most β-lactams including carbapenems; (2) CRKP is generally only susceptible to a few antibiotics, including colistin, tigecycline, ceftazidime/avibactam and one or more aminoglycosides; (3) it is difficult for most drugs to reach the minimal inhibitory concentration (MIC) in the cerebrospinal fluid (CSF) because of the low penetration of the blood-brain barrier. To overcome these disadvantages, many cases and clinical studies have attempted to treat CNSIs caused by multidrug-resistant...
bacteria using intraventricular (IVT) injections of antibiotics to increase drug concentrations in the CSF. Here, we describe a case of CRKP intracranial infection after neurosurgery, that was successfully treated with intravenous (IV) plus IVT tigecycline-amikacin therapy with the participation of clinical pharmacists.

2. Case Report
A 57-year-old man underwent hematoma removal from an epidural and subdural and skull depression fracture repair plus debridement suture because of an open craniocerebral injury. An epidural drain was inserted. After the operation, vancomycin 1 g q12h IV was administered empirically due to severe contamination from a head skin laceration. On hospital day 8, the patient presented with dyspnea, high fever (peak at 39.5 °C) and seizures associated. A computed tomography scan of the chest and head showed obvious exudative lesions in both lower lungs with atelectasis, multiple cerebral contusions and laceration, paranasal sinus effusion, and local edema in left frontal lobe. The patient was diagnosed with pneumonia and a highly suspected intracranial infection. On hospital day 9, the white blood cell count (WBC) increased to 30.29 × 10⁹/L, C-reactive protein was 200 mg/L and procalcitonin (PCT) was 2.26 mg/L. Lumbar CSF showed white blood cell count was 885 × 10⁶/L, leukocyte multinucleate ratio (LMR) was 97.7%, protein was 281.7 mg/dL and glucose was 0.17 mmol/L (Table 1). In the meantime, Preliminary Gram staining showed gram-negative rods in the CSF and sputum. Empirical IV meropenem 2 g q8h and cefoperazone-sulbactam sodium(2:1) 3 g q8h were used for the treatment of pneumonia and intracranial infections. On hospital day 10, sputum culture revealed CRKP which was only sensitive to tigecycline, amikacin and imipenem. In addition, the drug sensitivity test, amikacin was adjusted to ciprofloxacin 0.4 g q8h IV. Seven days later, the patient’s body temperature and infection indicators returned to normal levels. Meanwhile, 3 consecutive sputum cultures from hospital day 29 yielded negative results. Eventually, the patient’s intracranial, skin soft tissue, and lung infections were all cured. On hospital day 38, the patient was transferred to the general ward for functional recovery. No side effects were observed during the dual IVT antibiotic therapy. Continued 6-month-follow-up showed no recurrence and the patient was able to walk slowly on his own.

3. Discussion
In recent years, CNSIs caused by multidrug-resistant A. baumannii and K. pneumoniae after neurosurgery have been reported continuously, which have caused serious global health problems. Due to the poor permeability of blood-brain barrier and lack of sensitivity of most drugs, IVT antibiotics therapy for intracranial infections becomes a hot topic. The 2017 Infectious Diseases Society of America’s Clinical Practice Guidelines for Healthcare-associated Ventriculitis and Meningitis support the use of IVT antimicrobials for the treatment of difficult-to-eradicate or multidrug-resistant CSF infections. Nowadays, a series of clinical studies revealed that IVT colistin can successfully treat patients with extremely drug-resistant A. baumannii meningitis/ventriculitis. Nevertheless, the neurotoxicity of intraventricular injection of colistin (as high as 21.7%) and the heterogeneous resistance to colistin monotherapy have restricted its further application.

Tigecycline is the first novel semisynthetic antimicrobial agent of glycyclines, which blocks t-RNA from entering ribosome site A by reversibly binding to the bacterial ribosome 30S subunit, resulting in inhibition of bacterial protein synthesis and bacterial growth. In addition, tigecycline effectively avoids the 2 genetic mechanisms of tetracycline resistance (efflux and ribosomal protection), by adding a glyyclamide moiety to the 9-position of minocycline, further expanding the broad-spectrum antibacterial activity of tetracycline. In vitro, tigecycline showed strong antibacterial activity against a variety of drug-resistant bacteria, including CRKP. The 2020 CHINET data showed that tigecycline was 90.9% sensitive to 8858 CRKP strains. Unfortunately, tigecycline also has poor CSF penetration and has not been

| Date       | Hospital day 5 | Hospital day 9 | Hospital day 13 | Hospital day 15 | Hospital day 18 | Hospital day 21 | Hospital day 25 | Hospital day 33 | Hospital day 41 | Hospital day 65 |
|------------|----------------|----------------|-----------------|-----------------|----------------|----------------|----------------|----------------|----------------|----------------|
| WBC(× 10⁶/L) | 2              | 885            | 836             | 1078            | 185            | 68             | 30             | 29             | 61             | 77             |
| LMR (%)    | 50             | 97.7           | 77.9            | 91.4            | 91.9           | 82.3           | 23.4           | 17.2           | 22.9           | 5.2            |
| Glucose (mmol/L) | 4.96         | 0.17           | 4.00            | 5.11            | 4.60           | 3.33           | 3.34           | 2.97           | 3.03           | 3.12           |
| Protein (mg/dL) | 18.1          | 281.7          | 90.9            | 134.6           | 60.1           | 102.8          | 64.8           | 89.1           | 103.2          | 104.0          |
approved by the FDA for CNSIs. A study on the drug concentration distribution of tigecycline in different tissues after a single dose of 100 mg in healthy adults showed that the ratio of CSF to serum AUC was only 0.11.\[11\]This is similar to the results obtained by Munyeza et al\[12\] to quantitatively determine the tigecycline content in rat brain tissue by liquid chromatography-tandem mass spectrometry (LC-MS/MS). A series of studies by Dandache et al\[13\], Lengerke et al\[14\], Ray et al,\[15\]and Pallotto et al\[16\]further showed that even in the presence of meningitis, the drug concentration of tigecycline in the CSF was still far lower than the MIC of pathogens. However, Mei et al\[17\] reported a case of multidrug-resistant \textit{K. pneumoniae} treated with IVT tigecycline, and the concentration of tigecycline in CSF was determined to be 17400–26400 ng/mL by LC-MS/MS, and the ratio of CSF to serum AUC calculated by the noncompartmental model was 48.9. Similarly, Wu et al\[18\] reported a case of multidrug-resistant \textit{K. pneumoniae} meningitis treated with 3 different doses of tigecycline (49 mg IV + 1 mg IVT q12h, 45 mg IV + 5 mg IVT q12h, and 40 mg IV + 10 mg IVT q12h), and the trough concentrations of tigecycline in CSF measured by LC-MS/MS were 0.313, 1.29, and 2.886 mg/L, respectively. The optimal trough concentration was obtained at the highest IVT tigecycline dosage, which was higher than the MIC (2 mg/L) of the pathogen. Soto-Hernández et al\[19\] reported a case of IVT tigecycline for the treatment of multidrug-resistant \textit{Klebsiella oxytogenogen} ventriculitis. Two hours after administration, the C\(_0\) of tigecycline in CSF was 178.9–310.1 mg/L by liquid chromatography-ultraviolet detection. Even after 6 hours, the drug concentration of tigecycline in CSF can still reach 35.4–41.3 mg/L, which is 15–20 times higher than the MIC (2 mg/L) of the pathogen. All 3 patients with CNSIs were cured without adverse reactions. Based on the current research, IVT antibiotics can significantly increase the drug concentration in the CSF, which is more conducive to the control of CNSIs.

At present, the treatment of CNSIs caused by CRKP is mainly based on intraventricular injection of an antibiotic combined with one or more other systemic intravenous antibiotics.\[18,21–23\] whereas there are few case reports of intraventricular injection of 2 antibiotics. Tsołak et al\[24\] reported 3 cases of CNSIs caused by extremely drug-resistant bacteria (one case was CRKP) successfully treated with combined IVT colistin and tigecycline, after the initial regimen of colistin administered alone through both IVT and IV routes had failed. The report shows that compared with IVT single colistin, combined administration is conducive to rapid microbial clearance and clinical improvement. Similarly, Nevekar et al\[21\] also reported the case of a patient with CRKP ventriculitis who underwent microbiological eradication with combination IVT antimicrobial therapy consisting of colistin and gentamicin plus systemic antimicrobials. In addition, a series of in vitro and in vivo synergistic tests\[26–28\] of CRKP showed that tigecycline combined with aminoglycosides had good synergistic effects. Synergistic experiments by Ni et al\[29,30\]further showed that compared with the colistin-tigecycline and colistin-aminoglycosides combinations, the tigecycline-aminoglycosides combination could effectively suppress the resistance selection in \textit{K. pneumoniae}.

Based on the pharmacokinetics of tigecycline in CSF and in vivo and in vitro synergies of tigecycline on CRKP, the patient had a homologous CRKP infection of the lung and central nervous system. The patient was administered IV plus IVT tigecycline-amikacin antinfective therapy for the first time. However, there is no uniform standard dose of IVT tigecycline. In this case, we administered intraventricular tigecycline 3 mg q12h because in previous reports, pathogens in the CSF were difficult to remove when low doses were administered.\[24,31\] Based on a systematic review of intraventricular aminoglycoside drugs, intraventricular amikacin 30 mg daily was administered.\[32\] Ultimately, the patient was treated with dual IVT combined with IV administration, the pathogenic bacteria in the CSF were eradicated after 7 days, and the CNSIs were completely cured after 14 days.

In conclusion, a man with CNSIs caused by CRKP was successfully treated with intravenous plus intraventricular tegacycline-amikacin. Therefore, intravenous plus intraventricular tigecycline-amikacin seems to be a safe and effective treatment for CNSIs. However, this report is only one case, and multicenter randomized studies are needed to demonstrate the efficacy and safety of dual intraventricular administration in patients.

### Table 2

Antibiotics susceptibility tests for \textit{Klebsiella pneumoniae}.

| Drug                          | MIC (mg/L): susceptibility interpretation* |
|-------------------------------|--------------------------------------------|
|                               | Hospital day 10; source: sputum            | Hospital day 11; source: CSF | Hospital day 18; source: CSF |
| Amoxicillin/Clavulanate       | ≥32: Resistant                             | ≥32: Resistant                | ≥32: Resistant                |
| Piperacillin/Tazobactam       | ≥128: Resistant                            | ≥128: Resistant               | ≥128: Resistant               |
| Cefuroxime                    | ≥64: Resistant                             | ≥64: Resistant                | ≥64: Resistant                |
| Cefoxitin                     | ≥64: Resistant                             | ≥64: Resistant                | ≥64: Resistant                |
| Ceftazidime                   | ≥64: Resistant                             | ≥64: Resistant                | ≥64: Resistant                |
| Ceftriaxone                   | ≥64: Resistant                             | ≥64: Resistant                | ≥64: Resistant                |
| Cefoperazone/Sulfobactam      | ≥64: Resistant                             | ≥64: Resistant                | ≥64: Resistant                |
| Ceftizone                     | ≥32: Resistant                             | ≥32: Resistant                | ≥32: Resistant                |
| Etanercept                    | ≥8: Resistant                              | ≥8: Resistant                 | ≥8: Resistant                 |
| Imipenem                      | ≥16: Resistant                             | ≥16: Resistant                | ≥16: Resistant                |
| Amikacin                      | ≤2: Susceptible                            | ≤2: Susceptible               | ≤2: Susceptible               |
| Gentamicin                    | 17mm: Susceptible (K-B)                    | 16mm: Susceptible (K-B)       | 20mm: Susceptible (K-B)       |
| Levofloxacin                  | ≥8: Resistant                              | ≥8: Resistant                 | ≥8: Resistant                 |
| Tigecycline                   | 2: Susceptible                             | 2: Susceptible                | 2: Susceptible                |
| Trimethoprim/Sulfonamide      | ≥320: Resistant                            | ≥320: Resistant               | ≥320: Resistant               |
| Ceftazidime/sulfobactam       | 17mm: Resistant (K-B)                      | 17mm: Resistant (K-B)         | 19mm: Resistant (K-B)         |

*Report time of the drug sensitivity test.

K-B = Kirby-Bauer disk diffusion method.
Author contributions
Conceptualization: Jiyao Li.
Data curation: Jiyao Li, Yiguuo Liu, Hongyan Wang.
Formal analysis: Jiyao Li.
Investigation: Jiyao Li, Guantao Wu, Yiguuo Liu, Hongyan Wang.
Project administration: Jiyao Li, Xiaoyan Xu.
Supervision: Xiaoyan Xu.
Writing—original draft: Jiyao Li.
Writing—review & editing: Jiyao Li, Xiaoyan Xu.

References
[1] Karvouniaris M, Brotis A, Tsiakos K, et al. Current perspectives on the diagnosis and management of healthcare-associated ventriculitis and meningitis. Infection and Drug Resistance 2022;15:697–721.
[2] Lee C-R, Lee JH, Park KS, et al. Global dissemination of carbapenemase-producing klebsiella pneumoniae: epidemiology, genetic context, treatment options, and detection methods. Front Microbiol. 2016;7:895.
[3] Fang YQ, Zhan RC, Jia W, et al. A case report of intraventricular tigecycline therapy for intracranial infection with extremely drug resistant Acinetobacter baumannii. Medicine (Baltim). 2017;96:e7703.
[4] Tunkel AR, Hasbun R, Bhimraj A, et al. 2017 Infectious Diseases Society of America’s clinical practice guidelines for healthcare-associated ventriculitis and meningitis. Clin Infect Dis. 2017;64:e34–65.
[5] De Bonis P, Lofrese G, Scoppettuolo G, et al. Intraventricular versus intravenous colistin for the treatment of extensively drug resistant Acinetobacter baumannii meningitis. Eur J Neurol. 2016;23:e6–75.
[6] Yu XB, Huang YY, Zhang XS, et al. Intraventricular colistin sulphate as a last resort therapy in a patient with multidrug-resistant Acinetobacter baumannii induced post-neurosurgical ventriculitis. Br J Clin Pharmacol. 2022;88:3490–494.
[7] Karasikos I, Galanis L, Baziaka F, et al. Intraventricular and intrathecal colistin as the last therapeutic resort for the treatment of multidrug-resistant and extensively drug-resistant Acinetobacter baumannii ventriculitis and meningitis: a literature review. Int J Antimicrob Agents. 2013;41:499–508.
[8] Band VI, Satola SW, Smith RD, et al. Colistin heteroresistance is largely undetected among carbapenem-resistant enterobacteriales collected in the United States. mBio 2021;12:e02881–20.
[9] Yaghoubi S, Zekiy AO, Krutova M, et al. Tigecycline antibacterial activity, clinical effectiveness, and mechanisms and epidemiology of resistance: narrative review. Eur J Clin Microbiol Infect Dis. 2021;41:1–20.
[10] Karlsson M, Lutgtring JD, Ansari U, et al. Molecular characterization of carbapenem-resistant enterobacteriales collected in the United States. Microb Drug Resist. 2022;28:389–97.
[11] Rodvold KA, Gotfried MH, Csek M, et al. Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. J Antimicrob Chemother. 2006;58:1221–9.
[12] Munyeza CF, Shobo A, Bainath S, et al. Development and validation of a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the quantification of tigecycline in rat brain tissues. Biomed Chromatogr. 2016;30:837–45.
[13] Dandache P, Nicolau DP, Sakoulas G, Tigecycline for the treatment of multidrug-resistant klebsiella pneumoniae meningitis. Infectious Diseases in Clinical Practice. 2009;17:66–8.
[14] Lengerke C, Haap M, Mayer F, et al. Low tigecycline concentrations in the cerebrospinal fluid of a neutropenic patient with inflamed meninges. Antimicrob Agents Chemother. 2011;55:449–50.
[15] Ray L, Levasseur K, Nicolau DP, et al. Cerebral spinal fluid penetration of tigecycline in a patient with Acinetobacter baumannii cerebritis. Ann Pharmacother. 2010;44:582–6.
[16] Pallotto C, Furro M, D’Avolio A, et al. Cerebrospinal fluid penetration of tigecycline. Scand J Infect Dis. 2014;46:69–72.
[17] Mei S, Luo X, Li X, et al. Development and validation of an LC-MSMS method for the determination of tigecycline in human plasma and cerebrospinal fluid and its application to a pharmacokinetic study. Biomed Chromatogr. 2016;30:1992–2002.
[18] Wu Y, Chen K, Zhao J, et al. Intraventricular administration of tigecycline for the treatment of multidrug-resistant bacterial meningitis after craniotomy: a case report. J Chemother. 2017;30:49–52.
[19] Soto-Hernández JL, Soto-Ramírez A, Pérez-neri I, et al. Multidrug-resistant Klebsiella oxytoca ventriculitis, successfully treated with intraventricular tigecycline: A case report. Clin Neurol Neurosurg. 2020;188:105592.
[20] Ni WT, Han YL, Liu J, et al. Tigecycline treatment for carbapenem-resistant enterobacteriales infections, a systematic review and meta-analysis. Medicine (Baltim). 2016;95:e3126.
[21] Gofman N, To K, Whitman M, et al. Successful treatment of ventriculitis caused by Pseudomonas aeruginosa and carbapenem-resistant Klebsiella pneumoniae with i.v. ceftazidime–avibactam and intrathecal amikacin. Am J Health Syst Pharm. 2018;75:953–7.
[22] Curebal B, Dalgic N, Bayraktar B. Intraventricular tigecycline for the treatment of shunt infection: a case in pediatrics. J Neurosurg Pediatr. 2018;23:247–50.
[23] Emroglu M, Alkan G, Turk Dagi H. Tigecycline therapy in an infant for ventriculoperitoneal shunt meningitis. Pediatrics. 2017;139:e20160963.
[24] Tsoaki V, Karvouniaris M, Manoulakas E, et al. Intraventricular CNS treatment with Colistin-Tigecycline combination: a case series. J Crit Care. 2018;47:338–41.
[25] Neveškar S, Cunningham KC, Greathouse KM, et al. Dual intraventricular plus systemic antibiotic therapy for the treatment of klebsiella pneumoniae carbapenemase-producing klebsiella pneumoniae ventriculitis. Ann Pharmacother. 2014;48:274–8.
[26] Demirlenk YM, Gücer LS, Uğuro D, et al. A meta-analysis for the role of aminoglycosides and tigecyclines in combined regimens against colistin- and carbapenem-resistant Klebsiella pneumoniae bloodstream infections. Eur J Clin Microbiol Infect Dis. 2022;41:761–69.
[27] Tang H-J, Lai C-C, Chen C-C, et al. Colistin-sparing regimens against Klebsiella pneumoniae carbapenemase-producing K. pneumoniae isolates: Combination of tigecycline or doxycycline and gentamicin or amikacin. J Microbiol Immunol Infect. 2019;52:273–81.
[28] Nulsopapon P, Nasomsong W, Pongchaidecha M, et al. The synergistic activity and optimizing doses of tigecycline in combination with aminoglycosides against clinical carbapenem-resistant Klebsiella pneumoniae isolates. Antibiotics (Basel). 2021;10:736.
[29] Li WT, Wei CQ, Zhou CF, et al. Tigecycline-amikacin combination effectively suppresses the selection of resistance in clinical isolates of KPC-producing klebsiella pneumoniae. Front Microbiol. 2016;7:1304.
[30] Ni WT, Yang DQ, Guan J, et al. In vitro and in vivo synergistic effects of tigecycline combined with aminoglycosides on carbapenem-resistant Klebsiella pneumoniae. J Antimicrob Chemother. 2021;76:2097–105.
[31] Long WY, Yuan J, Liu J, et al. Multidrug resistant brain abscess due to KPC-producing klebsiella pneumoniae carbapenemase-producing K. pneumoniae isolate. Infection and Drug Resistance 2022;15:697–721.